Your browser doesn't support javascript.
loading
Synergism of small molecules targeting VDAC with sorafenib, regorafenib or lenvatinib on hepatocarcinoma cell proliferation and survival.
Ventura, C; Junco, M; Santiago Valtierra, F X; Gooz, M; Zhiwei, Y; Townsend, D M; Woster, P M; Maldonado, E N.
Afiliación
  • Ventura C; Department of Drug Discovery & Biomedical Sciences, Medical University of South Carolina, Charleston, SC, USA; Institute for Immunological and Physiopathological Studies (IIFP), National Scientific and Technical Research Council (CONICET), Argentina.
  • Junco M; Department of Drug Discovery & Biomedical Sciences, Medical University of South Carolina, Charleston, SC, USA.
  • Santiago Valtierra FX; Department of Drug Discovery & Biomedical Sciences, Medical University of South Carolina, Charleston, SC, USA.
  • Gooz M; Department of Drug Discovery & Biomedical Sciences, Medical University of South Carolina, Charleston, SC, USA.
  • Zhiwei Y; Department of Drug Discovery & Biomedical Sciences, Medical University of South Carolina, Charleston, SC, USA.
  • Townsend DM; Department of Drug Discovery & Biomedical Sciences, Medical University of South Carolina, Charleston, SC, USA.
  • Woster PM; Department of Drug Discovery & Biomedical Sciences, Medical University of South Carolina, Charleston, SC, USA.
  • Maldonado EN; Department of Drug Discovery & Biomedical Sciences, Medical University of South Carolina, Charleston, SC, USA; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA. Electronic address: maldona@musc.edu.
Eur J Pharmacol ; 957: 176034, 2023 Oct 15.
Article en En | MEDLINE | ID: mdl-37652292

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / NAD Límite: Humans Idioma: En Revista: Eur J Pharmacol Año: 2023 Tipo del documento: Article País de afiliación: Argentina

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / NAD Límite: Humans Idioma: En Revista: Eur J Pharmacol Año: 2023 Tipo del documento: Article País de afiliación: Argentina